

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED

精優藥業控股有限公司\*

(incorporated in Bermuda with limited liability)

(Stock Code: 00858)

### POLL RESULTS OF THE SPECIAL GENERAL MEETING HELD ON 4 JULY 2013

The Board is pleased to announce that the ordinary resolution regarding the connected and major transaction as contemplated under the Acquisition Agreement was duly passed by way of poll by the Independent Shareholders at the SGM.

Reference is made to the announcements of Extrawell Pharmaceutical Holdings Limited (“**Company**”) dated 23 February 2013 and 27 February 2013 and the circular (“**Circular**”) to the shareholders of the Company dated 18 June 2013 regarding the connected and major transaction as contemplated under the Acquisition Agreement. Terms used herein shall have the same meanings as defined in the Circular unless the context requires otherwise.

#### POLL RESULTS OF THE SGM

Pursuant to Rule 13.39(5) of the Listing Rules, the Board is pleased to announce that the following ordinary resolution (“**Resolution**”) was duly passed by the Independent Shareholders by way of poll at the SGM held on 4 July 2013:

Resolution		Number of votes (%)	
		For	Against
1.	To consider and approve the supplemental agreement (the “Supplemental Agreement”) dated 23 February 2013 to the acquisition agreement dated 27 July 2007 (together with the Supplemental Agreement, the “Acquisition Agreement”) and entered into between Mr. Ong Cheng Heang as vendor and Extrawell (BVI) Limited as purchaser in respect of the sale and purchase of 49% interest in the share capital of Smart Ascent Limited and the transactions contemplated thereby, including but not limited to the issue of the zero coupon convertible bonds for an aggregate principal amount of HK\$641,300,000 as part consideration on and subject to the terms of the Acquisition Agreement.	166,043,424 Shares (100.00%)	0 Shares (0.00%)

As at the date of the SGM, the total number of issued Shares was 2,290,000,000. The Vendor, Dr. Mao and their respective associates (including JNJ Investments Limited and Fudan Pharmaceutical Limited which were indirectly controlled by Dr. Mao), and any other connected persons of the Company who were materially interested in the Acquisition, were required to abstain from voting on the Resolution at the SGM. As such, the total number of Shares entitling the Independent Shareholders to attend and vote for or against the Resolution at the SGM was 1,809,400,000, representing approximately 79.01% of the total issued share capital of the Company as at the date of the SGM. There were no Shares in issue entitling the Shareholders to attend and vote only against the Resolution at the SGM.

The Company's Hong Kong branch share registrar and transfer office, Tricor Tengis Limited, was appointed as the scrutineer at the SGM for the vote-taking.

By order of the Board  
**Extrawell Pharmaceutical Holdings Limited**  
**Xie Yi**  
*Director*

Hong Kong, 4 July 2013

*As at the date of this announcement, the executive Directors are Dr. Mao Yumin, Dr. Xie Yi, Dr. Lou Yi and Ms. Wong Sau Kuen, and the independent non-executive Directors are Mr. Fang Lin Hu, Mr. Xue Jing Lun and Ms. Jin Song.*

\* *For identification purpose only*